Carcinoma, Non-Small-Cell Lung

"Carcinoma, Non-Small-Cell Lung" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.

Descriptor ID	D002289
MeSH Number(s)	C04.588.894.797.520.109.220.249 C08.381.540.140.500 C08.785.520.100.220.500
Concept/Terms	Carcinoma, Non-Small-Cell Lung Carcinoma, Non-Small-Cell Lung Carcinoma, Non Small Cell Lung Carcinomas, Non-Small-Cell Lung Lung Carcinoma, Non-Small-Cell Lung Carcinomas, Non-Small-Cell Non-Small-Cell Lung Carcinomas Nonsmall Cell Lung Cancer Non-Small-Cell Lung Carcinoma Non Small Cell Lung Carcinoma Carcinoma, Non-Small Cell Lung Non-Small Cell Lung Cancer

Below are MeSH descriptors whose meaning is more general than "Carcinoma, Non-Small-Cell Lung".

Diseases [C]
Neoplasms [C04]
Neoplasms by Site [C04.588]
Thoracic Neoplasms [C04.588.894]
Respiratory Tract Neoplasms [C04.588.894.797]
Lung Neoplasms [C04.588.894.797.520]
Bronchial Neoplasms [C04.588.894.797.520.109]
Carcinoma, Bronchogenic [C04.588.894.797.520.109.220]
Carcinoma, Non-Small-Cell Lung [C04.588.894.797.520.109.220.249]
Respiratory Tract Diseases [C08]
Lung Diseases [C08.381]
Lung Neoplasms [C08.381.540]
Carcinoma, Bronchogenic [C08.381.540.140]
Carcinoma, Non-Small-Cell Lung [C08.381.540.140.500]
Respiratory Tract Neoplasms [C08.785]
Lung Neoplasms [C08.785.520]
Bronchial Neoplasms [C08.785.520.100]
Carcinoma, Bronchogenic [C08.785.520.100.220]
Carcinoma, Non-Small-Cell Lung [C08.785.520.100.220.500]

Below are MeSH descriptors whose meaning is related to "Carcinoma, Non-Small-Cell Lung".

Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Non-Small-Cell Lung".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Carcinoma, Non-Small-Cell Lung" by people in this website by year, and whether "Carcinoma, Non-Small-Cell Lung" was a major or minor topic of these publications.

Bar chart showing 86 publications over 24 distinct years, with a maximum of 8 publications in 2011 and 2016

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	1	0	1
1997	1	0	1
1999	0	1	1
2000	0	1	1
2003	2	0	2
2004	2	1	3
2005	3	0	3
2006	4	0	4
2007	3	0	3
2008	5	0	5
2009	2	1	3
2010	2	1	3
2011	8	0	8
2012	7	0	7
2013	3	1	4
2014	5	2	7
2015	4	0	4
2016	8	0	8
2017	1	1	2
2018	4	0	4
2019	4	0	4
2020	4	0	4
2021	3	0	3
2022	1	0	1

Below are the most recent publications written about "Carcinoma, Non-Small-Cell Lung" by people in Profiles.

Varlotto JM, Sun Z, Ky B, Upshaw J, Fitzgerald TJ, Diehn M, Lovly C, Belani C, Oettel K, Masters G, Harkenrider M, Ross H, Ramalingam S, Pennell NA. A Review of Concurrent Chemo/Radiation, Immunotherapy, Radiation Planning, and Biomarkers for Locally Advanced Non-small Cell Lung Cancer and Their Role in the Development of ECOG-ACRIN EA5181. Clin Lung Cancer. 2022 11; 23(7):547-560.

View in: PubMed
Ta R, Bozovic G, Wilson JL, Bankier AA, VanderLaan PA. The impact of pathology grossing protocol measures to improve pathologic nodal staging in lung cancer. Cancer Treat Res Commun. 2021; 29:100488.

View in: PubMed
Addeo A, Friedlaender A, Banna GL, Weiss GJ. TMB or not TMB as a biomarker: That is the question. Crit Rev Oncol Hematol. 2021 Jul; 163:103374.

View in: PubMed
Varlotto JM, Sun Z, Ky B, Upshaw J, Katz SI, Fitzgerald TJ, Wakelee H, Diehn M, Mankoff DA, Lovely C, Belani C, Oettel K, Masters G, Ramalingam S, Pennell NA. A Review of Immunotherapy for Stage III and Metastatic Non-Small Cell Lung Cancer and the Rationale for the ECOG-ACRIN EA5181 Study. Oncologist. 2021 06; 26(6):523-532.

View in: PubMed
Agrawal V, Benjamin KT, Ko EC. Radiotherapy and Immunotherapy Combinations for Lung Cancer. Curr Oncol Rep. 2020 11 19; 23(1):4.

View in: PubMed
Aghdam N, McGunigal M, Wang H, Repka MC, Mete M, Fernandez S, Dash C, Al-Refaie WB, Unger KR. Ethnicity and insurance status predict metastatic disease presentation in prostate, breast, and non-small cell lung cancer. Cancer Med. 2020 08; 9(15):5362-5380.

View in: PubMed
Sehgal K, Bulumulle A, Brody H, Gill RR, Macherla S, Qilleri A, McDonald DC, Cherry CR, Shea M, Huberman MS, VanderLaan PA, Weiss GJ, Walker PR, Costa DB, Rangachari D. Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non-small-cell Lung Cancer. Clin Lung Cancer. 2021 05; 22(3):e379-e389.

View in: PubMed
Friedlaender A, Drilon A, Weiss GJ, Banna GL, Addeo A. KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures. Cancer Treat Rev. 2020 Apr; 85:101978.

View in: PubMed
Riano I, Cristancho C, Treadwell T. Stevens-Johnson Syndrome-Like Reaction After Exposure to Pembrolizumab and Recombinant Zoster Vaccine in a Patient With Metastatic Lung Cancer. J Investig Med High Impact Case Rep. 2020 Jan-Dec; 8:2324709620914796.

View in: PubMed
Sun Y, Han Y, Song M, Charoensinphon N, Zheng J, Qiu P, Wu X, Xiao H. Inhibitory effects of nobiletin and its major metabolites on lung tumorigenesis. Food Funct. 2019 Nov 01; 10(11):7444-7452.

View in: PubMed

People

Explore

Similar Concepts

Top Journals